
The 5-year STRATCANS study demonstrates safe and effective risk-stratified active surveillance for prostate cancer. Among 297 men with CPG1 or CPG2 disease, 72.1% remained treatment-free, with only 11.7% progressing to CPG≥3. STRATCANS showed superior predictive accuracy for progression compared to other stratification methods. It offers durable monitoring, high compliance, low treatment rates, and tailored follow-up based on progression risks, with tools available for clinical implementation.
Like
Save
Share